S. Taylor

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

W. R. Bishop, P. Kirschmeier, B. Long, 2009, International journal of cancer.

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

W. R. Bishop, P. Kirschmeier, Ming Liu, 2008, Gynecologic oncology.

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)

P. Kirschmeier, Ming Liu, A. Basso, 2007, Anti-cancer drugs.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

K. Cox, P. Kirschmeier, R. Doll, 2018, ACS medicinal chemistry letters.

Best Practices for Clinical Research Biomarker Studies Using the nCounter ® Platform: Strategies to Control for Variability

G. Gonye, K. Maclean, Erin Piazza, 2018 .

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

P. Kirschmeier, B. Long, Y. Hsieh, 2009, International journal of cancer.